Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected ...

In a comprehensive study, researchers from the Department of Epidemiology at the Faculty of Medicine at the University of ...

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrol ...

Using data from over 1.5 million patients from 47 studies, the researchers analysed the association between four autoimmune ...

Zenas BioPharma, Inc. ( ($ZBIO) ) has released its Q2 earnings. Here is a breakdown of the information Zenas BioPharma, Inc. presented to its ...

Autolus Therapeutics ( ($AUTL) ) has released its Q2 earnings. Here is a breakdown of the information Autolus Therapeutics presented to its ...

Adicet Bio (NASDAQ:ACET), a biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer, reported its second quarter 2025 earnings on August 7 ...

High adherence to the Mediterranean diet is associated with a reduced risk for SLE, with the relationship partially mediated by certain liver and kidney function biomarkers.

Net loss was $23.0 million, or $0.31 per basic and diluted share, for the second quarter of 2025. This net loss includes non-cash charges of $3.4 million that consisted primarily of share-based ...

Phase 1b/2a immune thrombocytopenia (ITP) trial FPI achieved, enrollment ongoing. Climb Bio is enrolling an open-label, dose-escalation Phase 1b/2a clinical trial of budoprutug in patients with ITP to ...